US Capitol Capsule: Washington's 2015 Biopharma Game Changers
This article was originally published in Scrip
The past year in Washington saw several events that were game changers for the biopharmaceutical industry – or whose outcomes could be in the future – such as the launch of President Barack Obama's Precision Medicine Initiative, the first US approval of a biosimilar, the departure of the FDA's commissioner and nomination of her successor and the adoption by the House of legislation aimed at overhauling the US biomedical enterprise.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.